TCG Crossover Management’s Dianthus Therapeutics DNTH Stock Holding History

TCG Crossover Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$163M	Hold	1,676,624	–	–	3.93%	7
2026 Q1	$141M	Hold	1,676,624	–	–	4.03%	6
2025 Q4	$69.1M	Hold	1,676,624	–	–	2.29%	13
2025 Q3	$66M	Buy	1,676,624 +175,000	+12%	+$4.47M	3.25%	8
2025 Q2	$28M	Hold	1,501,624	–	–	3.2%	14
2025 Q1	$27.2M	Hold	1,501,624	–	–	3.72%	9
2024 Q4	$32.7M	Buy	+1,501,624	New	+$38.6M	3.2%	11
2022 Q4	–	Sell	-132,758	Closed	-$3M	–	23
2022 Q3	$3M	Hold	132,758	–	–	0.9%	17
2022 Q2	$2.55M	Hold	132,758	–	–	1.08%	19
2022 Q1	$6.16M	Sell	132,758 -6,131	-4%	-$335K	2.47%	15
2021 Q4	$9.84M	Buy	+138,889	New	+$14M	4.61%	11

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

TCG Crossover Management's DNTH Position: Q2 2026 in Review

TCG Crossover Management held its Dianthus Therapeutics (DNTH) position steady in Q2 2026 at 1,676,624 shares worth $163M. The position accounts for 3.93% of the portfolio, ranked #7.

TCG Crossover Management first reported a position in DNTH in Q4 2021 and has held it in 11 quarters since. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

TCG Crossover Management held 1,676,624 shares of Dianthus Therapeutics worth $163M as of Q2 2026.
TCG Crossover Management left its Dianthus Therapeutics share count unchanged in Q2 2026.
Dianthus Therapeutics made up 3.93% of TCG Crossover Management's portfolio in Q2 2026, its #7 holding.
TCG Crossover Management first reported a position in Dianthus Therapeutics in Q4 2021 and has held it in 11 quarters since.
268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.